Herzass

Herzass is an oral medication that contains acetylsalicylic acid, a non‑steroidal anti‑inflammatory drug (NSAID). Marketed in the European Union as an over‑the‑counter (OTC) tablet, it belongs to the analgesic, antipyretic, and antiplatelet therapeutic classes and carries ATC code B01AC06. The formulation is absorbed after swallowing, providing rapid onset for pain relief, fever reduction, and platelet inhibition. It is intended for short‑term use in adults and is not a prescription medication.

Herzass is commonly used for several short‑term therapeutic purposes related to pain, fever, inflammation, and cardiovascular risk reduction.

- Relief of mild to moderate headache, toothache, or musculoskeletal pain. - Reduction of fever associated with common infections or inflammatory conditions. - Management of minor inflammatory complaints such as sore throat or minor joint discomfort. - Prevention of arterial thrombosis in individuals at risk for myocardial infarction or ischemic stroke, when recommended by a healthcare professional.

Like other NSAIDs, acetylsalicylic acid can cause adverse reactions that vary in frequency and severity.

Common: - Upset stomach, nausea, or indigestion. - Mild headache or dizziness. - Minor bruising or prolonged bleeding from cuts. - Skin rash or mild itching.

Serious: - Gastrointestinal ulceration or bleeding. - Severe allergic reaction such as anaphylaxis or angioedema. - Hemorrhagic stroke or intracranial bleeding.

When considering Herzass, several precautionary measures should be reviewed to minimize risk.

- Avoid use in individuals with known hypersensitivity to aspirin or other NSAIDs. - Do not use in children or teenagers with viral infections due to risk of Reye’s syndrome. - Caution in patients with a history of peptic ulcer disease, gastrointestinal bleeding, or chronic kidney disease. - Assess bleeding risk before use in patients on anticoagulants, antiplatelet agents, or with coagulation disorders. - Limit use during pregnancy, especially in the third trimester, unless directed by a physician. - Discontinue before planned surgery to reduce intra‑operative bleeding.

Herzass may interact with other medicines, altering its effectiveness or increasing the chance of adverse effects.

Avoid: - Concurrent use with other NSAIDs (e.g., ibuprofen, naproxen) due to additive gastrointestinal toxicity. - Combination with anticoagulants such as warfarin or direct oral anticoagulants, which can markedly increase bleeding risk. - Use with selective serotonin reuptake inhibitors (SSRIs) or other drugs that affect platelet function, as bleeding risk may be enhanced.

Use with caution: - Co‑administration with corticosteroids may raise ulcer risk. - Concurrent use with antihypertensive agents (e.g., ACE inhibitors, diuretics) may reduce their blood‑pressure‑lowering effect. - Taking with alcohol can increase stomach irritation and bleeding potential.